A Combination of Pathway-Targeted Inhibitor with DNA-Repair Inhibitor: Preclinical Efficacy of Zactima and Olaparib in Triple Negative Subset of Breast Cancer.

被引：0
|
作者：
Dey, N. [1 ]
Wu, H. [1 ]
Sun, Y. [1 ]
De, P. [1 ]
Leyland-Jones, B. [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-18-02
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
    Liang, Diana H.
    Choi, Dong Soon
    Ensor, Joe E.
    Kaipparettu, Benny A.
    Bass, Barbara L.
    Chang, Jenny C.
    CANCER LETTERS, 2016, 376 (02) : 249 - 258
  • [42] Preclinical characterization of the novel TTK kinase inhibitor S81694 for the treatment of triple negative breast cancer
    Colombo, Riccardo
    Burbridge, Mike
    Rodriguez, Marianne
    Cantero, Frederique
    Caldarelli, Marina
    Giorgini, Maria Laura
    Sola, Francesco
    Ballinari, Dario
    Ciomei, Marina
    Bosotti, Roberta
    Montagnoli, Alessia
    Lsacchi, Antonella
    Donati, Daniele
    Galvani, Arturo
    CANCER RESEARCH, 2015, 75
  • [43] Preclinical analysis of synergistic antitumor effect of eribulin and HDAC inhibitor for triple-negative breast cancer cells
    Oba, Takaaki
    Izumi, Hiroto
    Ito, Ken-ichi
    CANCER RESEARCH, 2018, 78 (13)
  • [44] An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer
    Rather, Gulam M.
    Szekely, Zoltan
    Bertino, Joseph R.
    CANCER RESEARCH, 2020, 80 (16)
  • [45] A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.
    Li, Huiping
    Zhang, Jiayang
    Yin, Rutie
    Song, Nan
    Zhang, Youzhong
    Zhang, Yu
    Zhang, Keqiang
    Pan, Hongming
    Wang, Ke
    Lou, Ge
    Li Guiling
    Zhang, Ben
    Wang, Quanren
    Gao, Yunong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] The Effect of Paclitaxel with a STAT3 Pathway Inhibitor on Metastasis in the Treatment of Triple Negative Breast Cancer
    Dincsoy, Adnan Berk
    Gedikli, Esra
    Ozturk, Suleyman Can
    Nikshiqi, Erblina
    Baris, Veysel Ozgur
    Karakoc, Elif
    Muftuoglu, Sevda
    Esendagli, Gunes
    Erdem, Aysen
    ACTA PHYSIOLOGICA, 2023, 240 : 45 - 45
  • [47] Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway
    Moon, Yong Wha
    Gosh, Mithun
    Park, Nahee
    Pandey, Kamal
    Katwal, Nar Bahadur
    Hong, Sa Deok
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor
    Ahmed, Kamal
    Koval, Alexey
    Xu, Jiabin
    Bodmer, Alexandre
    Katanaev, Vladimir L.
    CANCER LETTERS, 2019, 449 : 45 - 55
  • [49] Preclinical efficacy of targeting c-MET by ARQ197 in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
    Sun, Y.
    Carlson, J. H.
    Lin, X.
    De, P. K.
    Williams, C.
    Hausman, S.
    Dey, N.
    Leyland-Jones, B. R.
    CANCER RESEARCH, 2016, 76
  • [50] Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
    Reichert, Zachery R.
    Devitt, Michael Edward
    Alumkal, Joshi J.
    Smith, David C.
    Caram, Megan Veresh
    Palmbos, Philip
    Vaishampayan, Ulka N.
    Alva, Ajjai Shivaram
    Braun, Thomas
    Yentz, Sarah Elizabeth
    Tsao, Phoebe A.
    Dreicer, Robert
    Cackowski, Frank Cameron
    Shah, Neel
    Dean, Emma
    Smith, Simon
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345